Vehicle Control

Phase 2

LLubris Bio Pty Ltd

Vehicle Control is one of 53 therapeutic programs targeting Crohn's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Crohn's DiseaseCompleted

Sjögren's SyndromeRecruiting

Moderate to Severe Glabellar LinesCompleted

Crohn's DiseasePhase 2

Completed

Sjögren's SyndromePhase 2

Recruiting

Moderate to Severe Glabellar LinesPhase 2

Completed

Competition

Competitive Landscape

97 competitors in Crohn's Disease

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

11 2

Omvoh

Eli Lilly

Phase 3

6 3

Leukine

Sanofi

Phase 3

4 4

Thalomid

Bristol-Myers Squibb

Phase 3

3 5

Mounjaro

Eli Lilly

Phase 3

2 6

Jyseleca

Gilead

Phase 3

2 7

Rinvoq

AbbVie

Phase 3

2 8

Velsipity

Pfizer

Phase 3

1 9

Biaxin

AbbVie

Phase 3

1 10

Orencia

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Sjögren's Syndrome

NCT07118241

Clinical

Trials by Indication[1]

Crohn's Disease1 trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Completed·CCelularity Incorporated·Phase 2·NCT01155362·50 enrolled

Moderate to Severe Glabellar Lines1 trial

A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection (YY003) for the Treatment of Moderate to Severe Glabellar Lines in Adults

Completed·CChongqing Claruvis Pharmaceutical Co., Ltd.·Phase 2·NCT06481475·149 enrolled

Sjögren's Syndrome1 trial

A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

Recruiting·LLubris Bio Pty Ltd·Phase 2·NCT07118241·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vehicle Control. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Vehicle Control. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Lubris Bio Pty Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: LLubris Bio Pty Ltd

Vehicle Control

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Crohn's Disease1 trial

Moderate to Severe Glabellar Lines1 trial

Sjögren's Syndrome1 trial

References

Drug Info

Quick Facts

Related News